The DOI matches its Crossref record; the references it cites are not checked yet.
Comprehensive T cell repertoire characterization of non-small cell lung cancer
Open accessAbstract
Immunotherapy targeting T cells is increasingly utilized to treat solid tumors including non-small cell lung cancer (NSCLC). This requires a better understanding of the T cells in the lungs of patients with NSCLC. Here, we report T cell repertoire analysis in a cohort of 236 early-stage NSCLC patients. T cell repertoire attributes are associated with clinicopathologic features, mutational and immune landscape. A considerable proportion of the most prevalent T cells in tumors are also prevalent in the uninvolved tumor-adjacent lungs and appear specific to shared background mutations or viral infections. Patients with higher T cell repertoire homology between the tumor and uninvolved tumor-adjacent lung, suggesting a less tumor-focused T cell response, exhibit inferior survival. These findings indicate that a concise understanding of antigens and T cells in NSCLC is needed to improve therapeutic efficacy and reduce toxicity with immunotherapy, particularly adoptive T cell therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast, in studies performed in patients with treatment-naïve and resected NSCLC, higher TCR clonality was observed in the uninvolved resected lung22.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [22]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 55 · Cited by 220
Metadata
- Authors
- Reuben, A., Zhang, J., Chiou, S.-H., Gittelman, R. M., Li, J., Lee, W.-C., Fujimoto, J., Behrens, C., Liu, X., Wang, F., Quek, K., Wang, C., Kheradmand, F., Chen, R., Chow, C.-W., Lin, H., Bernatchez, C., Jalali, A., Hu, X., Wu, C.-J., Eterovic, A. K., Parra, E. R., Yusko, E., Emerson, R., Benzeno, S., Vignali, M., Wu, X., Ye, Y., Little, L. D., Gumbs, C., Mao, X., Song, X., Tippen, S., Thornton, R. L., Cascone, T., Snyder, A., Wargo, J. A., Herbst, R., Swisher, S., Kadara, H., Moran, C., Kalhor, N., Zhang, J., Scheet, P., Vaporciyan, A. A., Sepesi, B., Gibbons, D. L., Robins, H., Hwu, P., Heymach, J. V., Sharma, P., Allison, J. P., Baladandayuthapani, V., Lee, J. J., Davis, M. M., Wistuba, I. I., Futreal, P. A., & Zhang, J.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Howard Hughes Medical Institute (US)
- Adaptive Biotechnologies (United States) (US)
- iRepertoire (United States) (US)
- Baylor College of Medicine (US)
- Yale Cancer Center (US)
- Fred Hutch Cancer Center (US)
- Corresponding author
- Zhang, Jiexin
- Zhang, Jianhua
- Davis, Mark M.
- Wistuba, Ignacio I.
- Futreal, P. Andrew
- Zhang, Jianjun
- ORCID
- Reuben, Alexandre
- Zhang, Jiexin
- Chiou, Shin-Heng
- Gittelman, Rachel M.
- Lee, Won-Chul
- Fujimoto, Junya
- Behrens, Carmen
- Liu, Xiaoke
- Quek, Kelly
- Wang, Chunlin
- Kheradmand, Farrah
- Chen, Runzhe
- Lin, Heather
- Bernatchez, Chantale
- Parra, Edwin Roger
- Benzeno, Sharon
- Vignali, Marissa
- Wu, Xifeng
- Ye, Yuanqing
- Little, Latasha D.
- Gumbs, Curtis
- Song, Xingzhi
- Cascone, Tina
- Wargo, Jennifer A.
- Herbst, Roy
- Swisher, Stephen
- Kadara, Humam
- Moran, Cesar
- Kalhor, Neda
- Zhang, Jianhua
- Scheet, Paul
- Vaporciyan, Ara A.
- Sepesi, Boris
- Gibbons, Don L.
- Hwu, Patrick
- Heymach, John V.
- Sharma, Padmanee
- Allison, James P.
- Lee, Jack J.
- Davis, Mark M.
- Wistuba, Ignacio I.
- Futreal, P. Andrew
- Zhang, Jianjun
- Venue
- Nature Communications
- Published
- 2020-01-30
- Volume
- 11
- Issue
- 1
- Pages
- 603-603
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC6992630
- OpenAlex
- W3003556485
- Cited by
- 220
- References
- 55
- Citations by year
- 2026: 17 · 2025: 26 · 2024: 35 · 2023: 35 · 2022: 39 · 2021: 42 · 2020: 26
- FWCI
- 13.09
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Rutgers University Community Repository (Rutgers University) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Welch Foundation
- Howard Hughes Medical Institute
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- non-small cell lung cancer, T cell receptor repertoire, tumor-infiltrating T cells, viral infection, immune landscape, mutational landscape, adoptive T cell therapy, immunotherapy, survival
- MeSH terms
- Adult, Aged, Carcinoma, Non-Small-Cell Lung, Clone Cells, Female, Humans, Lung, Lung Neoplasms, Lymphocyte Activation, Male, Middle Aged, Mutation, T-Lymphocytes, Survival Analysis, Lymphocyte Count, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comprehensive T cell repertoire characterization of non-small cell lung cancer. https://app.cochat.ai/papers/10.1038/s41467-019-14273-0
- The paper
- Reuben, A., Zhang, J., Chiou, S.-H., Gittelman, R. M., Li, J., Lee, W.-C., Fujimoto, J., Behrens, C., Liu, X., Wang, F., Quek, K., Wang, C., Kheradmand, F., Chen, R., Chow, C.-W., Lin, H., Bernatchez, C., Jalali, A., Hu, X., . . . Zhang, J. (2020). Comprehensive T cell repertoire characterization of non-small cell lung cancer. Nature Communications. https://doi.org/10.1038/s41467-019-14273-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.